© The Canadian Journal of Urology™; 19(Supplement 1); October 2012
37.
Tamimi NA, Mincik I, Haughie S. A placebo-controlled study
investigating the efficacy and safety of the phosphodiesterase
type 5 inhibitor UK-369,003 for the treatment of menwith lower
urinary tract symptoms associatedwith clinical benign prostatic
hyperplasia.
BJU Int
2010;106(5):674-680.
38.
Egerdie RB, Auerbach S, Roehrborn CG et al. Tadalafil 2.5 or
5
mg administered once daily for 12 weeks in med with both
erectile dysfunction and signs and symptoms of benign prostatic
hyperplasia: results of a randomized, placebo-controlled,
double-blind study.
J Sex Med
2011;9(1):271-281.
39.
Nickel JC, Méndez-Probst CE, Whelan TF, Paterson RF, Razvi H.
2010
Update: Guidelines for themanagement of benign prostatic
hyperplasia.
Can Urol Assoc J
2010;4(5):310-316.
17
Benign prostatic hyperplasia (BPH) management in the primary care setting
